Novel targeted therapies have become standard treatment for chronic lymphocytic leukemia due to their ability to delay progression of this slow-growing malignancy. Nevertheless, CLL remains incurable.

Lori A. Leslie, MD, an expert on CLL, talks about factors that influence treatment decisions. Lori A. Leslie, MD: Let’s talk about the types of patient factors we think about when selecting a ...

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately ...

Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk chronic lymphocytic leukemia (CLL), ...

Brian Koffman, MD, and Roy Beveridge, MD, discuss the financial burdens of Bruton tyrosine kinase inhibitor therapy and considerations for oral therapy vs infusion therapy. Ryan Haumschild, PharmD, MS ...

ONO Pharmaceutical Co (($OPHLF)) announced an update on their ongoing clinical study. Study Overview: ONO Pharmaceutical Co. Ltd is conducting a ...

Researchers sought to determine whether brexucabtagene autoleucel would improve response rates among patients with relapsed or refractory CLL.

A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows ...

New EORTC guidelines establish meaningful change thresholds for symptom burden, physical condition/fatigue, and worries/fears in R/R CLL or SLL patients. Thresholds help identify significant ...